You are here: Industry Insights > 2020

News List

With Anlotinib Sold over RMB4 Billion in 2020, Which will be the Next Blockbuster of Sino Biopharmaceutical? PharmaSources/Caicai
May 31, 2021
Sino Biopharmaceutical has recently released its 2020 annual results, with total revenue of RMB23.647 billion, down 2.4% year on year, net profit attributable to the parent of RMB2.771 billion, up 0.3% year on year
A Brief Overview of COVID-19 Pandemic in 2020 Lin Zhang
March 18, 2021
2020 has been a challenging year across the globe. SARS-CoV-2, the virus that causes COVID-19 and is believed to originate from bats, quickly spread into a global pandemic.
Biosimilars 2020: Low Approvals, but Significant Advances Neeta Ratanghayra
March 18, 2021
2020 has been a tough year. The pandemic posed an array of challenges to the healthcare system and the global biopharmaceutical industry both rose to the challenges and seized opportunities.
A Review of the Export Data of China’s Plant Extract Market in 2020 and Potential Varieties PharmaSources.com
March 18, 2021
In 2020, the outbreak of the pandemic stimulated consumer demand for naturally sourced plant extracts, however, China’s export value of plant extracts in the first half of 2020 reached USD1.265 billion, up only 1.08% year on year.
Junshi’s Anti-PD-1 Drug Achieved Sales of RMB1.3 Billion in 2020 PharmaSources/Caicai
March 12, 2021
Junshi Biosciences has recently announced its 2020 annual performance preview, according to which, it achieved operating income of RMB1.595 billion, up 105.77% year on year, mainly thanks to the sales revenue growth of its anti-PD-1 drug.
Qilu Pharmaceutical Achieved Staggering Sales of Bevacizumab of RMB1.8 Billion in 2020 PharmaSources/Caicai
March 04, 2021
According to industry news, Qilu Pharmaceutical achieved sales of bevacizumab (trade name: Ankeda) of about RMB1.8 billion in 2020.
A Review of Chinese-produced Class 1 New Drugs from 2018 to 2020 PharmaSources/Caicai
January 28, 2021
From 2018 to 2020, the marketing of Chinese-produced Class 1 new drugs entered the harvest period, with a total of 32 marketed (Chinese-produced Class 1 new drugs here refer to drugs registered under the classification of chemical drugs 1 and therapeutic.
Production Applications of Chinese New Drugs in 2020 H1: Five Class 1 New Chemical Drugs, Two Anti-PD-1 Monoclonal Antibodies and Two CAR T-Cell Products Applied for Production for the First Time PharmaSources/Dopine
December 24, 2020
According to the Insight database, the CDE generated 50 marketing application acceptance numbers for Chinese new drugs in 2020 H1,...
2020 Zhejiang Export Commodity Online Fair “Middle East – APIs session” is now launched! PharmaSources.com
December 22, 2020
The portals for the “Middle East - APIs session” is now launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as Middle East buyers online.
2020 Zhejiang Export Commodity Online Fair “USA – Natural Extracts Session” is launched now! PharmaSources.com
December 21, 2020
The portals for the “USA - Natural Extracts session” is officially launched to welcome the participation of both pharmaceutical suppliers located in Zhejiang Province of China, as well as USA buyers online.